Clinical trials
Alzheimer s Disease clinical trials
Below are recruiting alzheimer s disease clinical trials, each written for real people, not researchers. We’re tracking 595 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03810794Recruiting
Acupuncture study for people with Alzheimer’s memory problems
This trial tests whether acupuncture can improve symptoms in people with Alzheimer’s disease. You may qualify if you have memory and thinking changes consistent with Alzheimer’s and meet imaging and brain-scan score requirements.
Shanghai, Shanghai MunicipalityAges 50–85 - NCT03821857RecruitingPhase 4
Study of hormone disruption effects on aging and Alzheimer’s
This trial studies how hormone (endocrine) disruption may affect aging and Alzheimer’s disease in women. It may help researchers understand why these effects can differ by sex and how to better assess or track risk over time.
Jacksonville, FloridaAges 60 years+ - NCT03851523Recruiting
Tracking memory changes in people with early Alzheimer’s symptoms
This study follows people over time to better understand how memory and thinking complaints progress in early Alzheimer’s disease (from “subjective cognitive decline” to mild cognitive problems). It may help researchers understand who is likely to decline and how symptoms change, which could support future treatments.
Barcelona, CataloniaAges 45 years+ - NCT05904132Recruiting
Brain stimulation therapy for early Alzheimer’s memory loss
This trial studies a “closed-loop” brain stimulation approach to improve symptoms in people with early Alzheimer’s-related memory problems. It may help by delivering stimulation based on your brain signals, if you meet the safety and diagnosis requirements.
Charlestown, MassachusettsAges 50–80 - NCT04436081RecruitingPhase 2
CBD oil without THC for agitation in Alzheimer’s dementia
This trial studies whether a THC-free CBD oil softgel can reduce agitation in people with Alzheimer’s-related dementia. It compares CBD to a control to see if it improves difficult behaviors and is safe over the study period.
Norfolk, VirginiaAges 50–90 - NCT04570085RecruitingPhase 3
Caffeine treatment to improve thinking in Alzheimer’s disease
This trial tests whether changing caffeine intake can improve thinking and brain function in people with Alzheimer’s disease. You may qualify if you can follow a low-caffeine diet and have stable Alzheimer’s treatment and sleep/heart conditions.
AmiensAges 50 years+ - NCT04575337Recruiting
Biomarker study to help detect Alzheimer’s early
This study looks for brain/biological “signals” (biomarkers) that may identify Alzheimer’s disease earlier, including stages before clear symptoms. You may be followed for about 5 years, with repeated memory and thinking testing to see how these signs relate to future diagnosis.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04661280RecruitingPhase 3
Donepezil compared with non-drug care for Alzheimer’s
This trial compares donepezil (a medicine for Alzheimer’s symptoms) against a non-drug treatment plan. It aims to see which approach helps people with Alzheimer’s who still have measurable thinking ability and specific Alzheimer’s test results.
ParisAges 50 years+ - NCT04740580RecruitingEarly Phase 1
Test glutathione for brain inflammation in Alzheimer’s
This early-stage study tests whether taking glutathione can affect brain “inflammation” and metabolism in people with Alzheimer’s disease. You might benefit from a new treatment approach, while helping researchers understand what works best for early Alzheimer’s-related brain changes.
Houston, TexasAges 55–85 - NCT04800588Recruiting
Computer tests to study early Alzheimer’s changes
This study uses computer and touch-screen tasks to measure thinking changes in people who may be in the early, symptom-free stage of Alzheimer’s disease. It aims to understand how these brain-related changes show up on testing, which could help future detection or tracking.
Berkeley, CaliforniaAges 18–89 - NCT04902703RecruitingPhase 2
GM-CSF drug trial for mild to moderate Alzheimer’s disease
This Phase 2 study tests whether sargramostim (a GM-CSF related medicine) is safe and can slow or improve Alzheimer’s symptoms. You might be a good fit if you have mild or moderate Alzheimer’s, positive amyloid testing, and can complete frequent visits with a close caregiver who knows you well.
Aurora, ColoradoAges 60–85 - NCT05194787Recruiting
Online tests to spot early Alzheimer’s changes
This study looks at whether online motor (movement) and thinking tasks can detect early changes related to Alzheimer’s disease. You may be able to take part if you’re over 50 and do not already have a diagnosis of dementia.
Hobart, TasmaniaAges 50 years+ - NCT05295615Recruiting
Pulsed magnetic treatment for mild to moderate Alzheimer’s
This trial tests whether a pulsed electromagnetic field (a non-drug device that uses magnetic pulses) can help people with mild to moderate Alzheimer’s. Participants typically stay on stable Alzheimer’s medicines and follow daily home treatments during the study.
Hackensack, New JerseyAges 50–100 - NCT05413655RecruitingPhase 2
Oral drug for mild Alzheimer’s disease symptoms
This Phase 2 trial tests an oral medicine (EX039) to see if it can help people with mild Alzheimer’s disease. It focuses on slowing or improving thinking and memory problems over time.
TaipeiAges 50–80 - NCT05509387Recruiting
Stronger brain stimulation to improve naming in Alzheimer’s
This trial tests whether a stronger form of gentle brain stimulation (tDCS) can help people with mild to moderate Alzheimer’s improve word-finding (naming). If you qualify, you’ll be assessed before and during the study to see whether the stimulation improves naming ability.
Toronto, OntarioAges 50–90 - NCT05582200Recruiting
PET brain scan to study inflammation cells in Alzheimer’s
This study uses a special PET brain scan to look at two types of brain immune cells in people with Alzheimer’s. It may help researchers better understand Alzheimer’s and how these cells change over time.
Houston, TexasAges 18–90 - NCT05597410Recruiting
Study of people at risk for Alzheimer’s in Shanghai
This study follows people who are closely related to someone diagnosed with Alzheimer’s to see who develops memory or brain changes over time. It may help researchers understand risk and early signs, which could guide prevention in families like yours.
Shanghai, Shanghai MunicipalityAges 50 years+ - NCT05667649RecruitingPhase 1
Stem cells injected in brain for mild to moderate Alzheimer’s
This Phase 1 study tests whether injecting your own (autologous) activated fat-derived stem cells into the brain is safe and potentially helpful for mild to moderate Alzheimer’s disease. The goal is to see how the treatment affects the brain and symptoms, using cells made from your own donated fat tissue.
Newport Beach, CaliforniaAges 45–80 - NCT05776641Recruiting
Light and sound training to help prevent Alzheimer’s memory loss
This study tests whether regular “gamma” light and sound stimulation can delay or prevent Alzheimer’s disease-related memory decline in people who are currently not showing dementia but are at higher risk. It uses brain testing (MRI and PET) and memory/language tests over about 13 months.
Boston, MassachusettsAges 55–90 - NCT05801380Recruiting
Tracking how well a medicine works in Alzheimer’s patients
This study looks at how effective a treatment is in people newly diagnosed with mild to moderate Alzheimer’s disease. It also involves health and medication history checks and likely stool (fecal) sample collection to monitor effects.
Manila, National Capital RegionAges 65 years+ - NCT05984524Recruiting
Gamma music therapy for mild Alzheimer's disease
This study tests whether a specially designed music intervention can help people with mild Alzheimer's disease. You listen to music with a gamma frequency beat, which may improve brain function and memory.
Boston, MassachusettsAges 50–95 - NCT06052163RecruitingPhase 2
Testing bumetanide for early Alzheimer's disease
This study tests whether a water pill called bumetanide can help people with early Alzheimer's disease. It involves taking the study drug, having MRI scans, and doing memory tests to see if it slows down symptoms.
Stanford, CaliforniaAges 50–85 - NCT06099587Recruiting
Brain scan study for early Alzheimer's memory changes
This study uses a special MRI scan to look at the brain's memory center in people with early memory concerns. It aims to better understand changes that happen in the very early stages of Alzheimer's disease.
RennesAges 50–80 - NCT06254469RecruitingPhase 3
PET scan study for memory decline with head injury or Alzheimer's risk
This trial uses a special PET scan tracer to see if it can predict who will get worse over time. It is for people with mild memory or thinking problems that may be linked to past head injuries or early Alzheimer's disease.
Evanston, IllinoisAges 45 years+
Hear when a new Alzheimer s Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alzheimer s disease?
- Yes. Clin2 currently lists 595 recruiting alzheimer s disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alzheimer s disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alzheimer s disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.